Skip to content
ChickenStockChickenStock
Research185750
Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical (185750) stock

KOSPI · Pharmaceuticals

KRW 61,000-0.49%(-300)

As of Nov 16, 3:17 PM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

10.59x

P/B

0.83x

P/S

0.47x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 478.5 billionKRW 18.6 billionKRW 20.4 billion+10.0%
Q1 2026Consolidated · Filed May 15, 2026KRW 447.8 billionKRW 14.1 billionKRW 12.6 billion+11.7%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 426.8 billionKRW 23.5 billionKRW 26.3 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 429.8 billionKRW 21 billionKRW 20.2 billion+4.1%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 434.8 billionKRW 23.6 billionKRW 19.4 billion+9.6%
Q1 2025Consolidated · Filed May 15, 2025KRW 401 billionKRW 12.5 billionKRW 11.9 billion+10.9%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 1.7 trillionKRW 80.6 billionKRW 77.8 billion—
FY2024Consolidated · Filed Mar 25, 2025KRW 1.6 trillionKRW 99.5 billionKRW 111.4 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
17.13%
Of trading value on Nov 13, 2026
Short-sale value
KRW 350 million
Previous 20-day average 14.77%
Net short position
260,621 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
609,407 shares
As of Nov 13, 2026 · 4.42% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 202617.13%KRW 350 million
Nov 12, 202617.34%KRW 300 million
Nov 11, 202619.09%KRW 210 million
Nov 10, 202616.84%KRW 120 million
Nov 9, 202619.48%KRW 170 million
Nov 6, 202615.34%KRW 190 million
Nov 5, 202613.34%KRW 370 million
Nov 4, 202617.69%KRW 220 million
Nov 3, 202615.13%KRW 210 million
Nov 2, 202612.13%KRW 380 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Chong Kun Dang Pharmaceutical (185750) stock information

KOSPI

Chong Kun Dang Pharmaceutical (185750) is listed on KOSPI. Its market capitalization is about KRW 842 billion. On trailing-twelve-month earnings the P/E ratio is 10.59, and the P/B ratio is 0.83. Return on equity is 7.8%. These figures are computed in-house from official filings and are reference information only.

Chong Kun Dang Pharmaceutical — frequently asked questions

What is the P/E ratio of Chong Kun Dang Pharmaceutical (185750)?
On a trailing-twelve-month basis, 185750 trades at a P/E ratio of 10.59. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Chong Kun Dang Pharmaceutical?
185750 has a market capitalization of about KRW 842 billion. The figure moves with the share price and is refreshed each trading day.
Does Chong Kun Dang Pharmaceutical pay a dividend?
185750 has a dividend yield of about 0.82%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.